Publicaciones en colaboración con investigadores/as de Pierre and Marie Curie University (17)

2019

  1. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System

    Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 11, pp. 301-309

  2. Parkinson’s disease with mild cognitive impairment: severe cortical thinning antedates dementia

    Brain Imaging and Behavior, Vol. 13, Núm. 1, pp. 180-188

  3. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients

    Parkinsonism and Related Disorders, Vol. 52, pp. 83-89

2017

  1. Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration

    Movement Disorders Clinical Practice, Vol. 4, Núm. 4, pp. 536-544

  2. Interhemispheric Connectivity Characterizes Cortical Reorganization in Motor-Related Networks After Cerebellar Lesions

    Cerebellum, Vol. 16, Núm. 2, pp. 358-375

2016

  1. Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma

    Cancer Investigation, Vol. 34, Núm. 1, pp. 39-44

2015

  1. VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab

    Journal of Neuro-Oncology, Vol. 121, Núm. 3, pp. 499-504

2014

  1. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma

    Cancer, Vol. 120, Núm. 24, pp. 3972-3980

  2. Management of elderly patients with gliomas

    Oncologist, Vol. 19, Núm. 12, pp. 1258-1267

2012

  1. Detection of IDH1 mutation in the plasma of patients with glioma

    Neurology, Vol. 79, Núm. 16, pp. 1693-1698

  2. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: Comparative analysis of the Macdonald, RECIST, RANO, and RECIST F criteria

    Neuro-Oncology, Vol. 14, Núm. 5, pp. 667-673

  3. Sporadic CNS hemangioblastomatosis, response to sunitinib and secondary polycythemia

    Journal of Neuro-Oncology

2011

  1. Erratum to: Sporadic CNS hemangioblastomatosis, response to sunitinib and secondary polycythemia (Journal of Neuro-Oncology DOI: 10.1007/s11060-011-0752- 9)

    Journal of Neuro-Oncology

2010

  1. Missing pieces in the Parkinson's disease puzzle

    Nature Medicine, Vol. 16, Núm. 6, pp. 653-661

2009

  1. Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication

    Journal of Neurochemistry, Vol. 110, Núm. 4, pp. 1321-1329

1996

  1. Glutamic acid decarboxylase mRNA expression in medial and lateral pallidal neurons in the MPTP-treated monkey and patients with Parkinson's disease

    PARKINSON'S DISEASE